An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism

A. Perenyi, G. Bagdy, M. Arato

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The effect of L-deprenyl on neuroleptic-induced parkinsonism was evaluated in eleven patients. No significant improvement was observed during the treatment with L-deprenyl in the overall assessment. Four patients, however, were considered responders, as their total scores on the modified version of the Neurological Rating Scale decreased by at least 50%. No somatic or mental complications were observed during the study. The pretreatment platelet monoamine oxidase activity of the responders was slightly but not significantly higher than that of the non-responders. The plasma prolactin (PRL) levels of the patients with high pretreatment levels decreased significantly during the administration of L-deprenyl.

Original languageEnglish
Pages (from-to)143-146
Number of pages4
JournalPharmacopsychiatria
Volume16
Issue number5
Publication statusPublished - 1983

Fingerprint

Selegiline
Parkinsonian Disorders
Antipsychotic Agents
Monoamine Oxidase
Prolactin
Therapeutics
Blood Platelets

ASJC Scopus subject areas

  • Medicine(all)

Cite this

An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism. / Perenyi, A.; Bagdy, G.; Arato, M.

In: Pharmacopsychiatria, Vol. 16, No. 5, 1983, p. 143-146.

Research output: Contribution to journalArticle

@article{1856a808fd1a4c06bbcbb1e01445f5e1,
title = "An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism",
abstract = "The effect of L-deprenyl on neuroleptic-induced parkinsonism was evaluated in eleven patients. No significant improvement was observed during the treatment with L-deprenyl in the overall assessment. Four patients, however, were considered responders, as their total scores on the modified version of the Neurological Rating Scale decreased by at least 50{\%}. No somatic or mental complications were observed during the study. The pretreatment platelet monoamine oxidase activity of the responders was slightly but not significantly higher than that of the non-responders. The plasma prolactin (PRL) levels of the patients with high pretreatment levels decreased significantly during the administration of L-deprenyl.",
author = "A. Perenyi and G. Bagdy and M. Arato",
year = "1983",
language = "English",
volume = "16",
pages = "143--146",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "5",

}

TY - JOUR

T1 - An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism

AU - Perenyi, A.

AU - Bagdy, G.

AU - Arato, M.

PY - 1983

Y1 - 1983

N2 - The effect of L-deprenyl on neuroleptic-induced parkinsonism was evaluated in eleven patients. No significant improvement was observed during the treatment with L-deprenyl in the overall assessment. Four patients, however, were considered responders, as their total scores on the modified version of the Neurological Rating Scale decreased by at least 50%. No somatic or mental complications were observed during the study. The pretreatment platelet monoamine oxidase activity of the responders was slightly but not significantly higher than that of the non-responders. The plasma prolactin (PRL) levels of the patients with high pretreatment levels decreased significantly during the administration of L-deprenyl.

AB - The effect of L-deprenyl on neuroleptic-induced parkinsonism was evaluated in eleven patients. No significant improvement was observed during the treatment with L-deprenyl in the overall assessment. Four patients, however, were considered responders, as their total scores on the modified version of the Neurological Rating Scale decreased by at least 50%. No somatic or mental complications were observed during the study. The pretreatment platelet monoamine oxidase activity of the responders was slightly but not significantly higher than that of the non-responders. The plasma prolactin (PRL) levels of the patients with high pretreatment levels decreased significantly during the administration of L-deprenyl.

UR - http://www.scopus.com/inward/record.url?scp=0021081673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021081673&partnerID=8YFLogxK

M3 - Article

C2 - 6140692

AN - SCOPUS:0021081673

VL - 16

SP - 143

EP - 146

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 5

ER -